Literature DB >> 30134346

PharmGKB summary: clozapine pathway, pharmacokinetics.

Caroline F Thorn1, Daniel J Müller2,3, Russ B Altman1,4, Teri E Klein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30134346      PMCID： PMC6449846          DOI： 10.1097/FPC.0000000000000347

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  9 in total

1.  Chemogenetic Seizure Control with Clozapine and the Novel Ligand JHU37160 Outperforms the Effects of Levetiracetam in the Intrahippocampal Kainic Acid Mouse Model.

Authors:  Jana Desloovere; Paul Boon; Lars Emil Larsen; Marie-Gabrielle Goossens; Jean Delbeke; Evelien Carrette; Wytse Wadman; Kristl Vonck; Robrecht Raedt
Journal:  Neurotherapeutics       Date:  2021-12-03       Impact factor: 6.088

2.  Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.

Authors:  C Okhuijsen-Pfeifer; M Z van der Horst; C A Bousman; B Lin; K R van Eijk; S Ripke; Y Ayhan; M O Babaoglu; M Bak; W Alink; H van Beek; E Beld; A Bouhuis; M Edlinger; I M Erdogan; A Ertuğrul; G Yoca; I P Everall; T Görlitz; K P Grootens; S Gutwinski; T Hallikainen; E Jeger-Land; M de Koning; M Lähteenvuo; S E Legge; S Leucht; C Morgenroth; A Müderrisoğlu; A Narang; C Pantelis; A F Pardiñas; T Oviedo-Salcedo; J Schneider-Thoma; S Schreiter; E Repo-Tiihonen; H Tuppurainen; M Veereschild; S Veerman; M de Vos; E Wagner; D Cohen; J P A M Bogers; J T R Walters; A E Anil Yağcıoğlu; J Tiihonen; A Hasan; J J Luykx
Journal:  Transl Psychiatry       Date:  2022-04-07       Impact factor: 7.989

3.  A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, and VKORC1 Genes.

Authors:  Camille Tron; Régis Bouvet; Marie-Clémence Verdier; Fabien Lamoureux; Benjamin Hennart; Christèle Dubourg; Eric Bellissant; Marie-Dominique Galibert
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-22

4.  Clozapine Metabolism is Associated With Absolute Neutrophil Count in Individuals With Treatment-Resistant Schizophrenia.

Authors:  Isabella R Willcocks; Sophie E Legge; Mariana Nalmpanti; Lucy Mazzeo; Adrian King; John Jansen; Marinka Helthuis; Michael J Owen; Michael C O'Donovan; James T R Walters; Antonio F Pardiñas
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

5.  Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia.

Authors:  Joomi Lee; Min-Gul Kim; Hyeon-Cheol Jeong; Kwang-Hee Shin
Journal:  Transl Clin Pharmacol       Date:  2021-03-10

6.  Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients.

Authors:  Lennart Kyllesø; Robert Løvsletten Smith; Øystein Karlstad; Ole A Andreassen; Espen Molden
Journal:  CNS Drugs       Date:  2021-08-20       Impact factor: 5.749

7.  Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome.

Authors:  Judith Weise; Georg Schomerus; Sven Speerforck
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-05-31       Impact factor: 3.731

8.  Metabolite Profiling of Clozapine in Patients Switching Versus Maintaining Treatment: A Retrospective Pilot Study.

Authors:  Lennart Kyllesø; Robert Løvsletten Smith; Birgit M Wollmann; Øystein Karlstad; Ole A Andreassen; Espen Molden
Journal:  J Clin Psychopharmacol       Date:  2022-08-02       Impact factor: 3.118

9.  VAE-Sim: A Novel Molecular Similarity Measure Based on a Variational Autoencoder.

Authors:  Soumitra Samanta; Steve O'Hagan; Neil Swainston; Timothy J Roberts; Douglas B Kell
Journal:  Molecules       Date:  2020-07-29       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.